# Prospective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local Therapy

> **NCT06478472** · NA · RECRUITING · sponsor: **The First Affiliated Hospital of Xiamen University** · enrollment: 36 (estimated)

## Conditions studied

- Marginal Zone Lymphoma

## Interventions

- **DRUG:** Orelabrutinib in combination with rituximab

## Key facts

- **NCT ID:** NCT06478472
- **Lead sponsor:** The First Affiliated Hospital of Xiamen University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-23
- **Primary completion:** 2027-06-23
- **Final completion:** 2027-06-23
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2024-07-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06478472

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06478472, "Prospective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local Therapy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06478472. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*